Skip to content
value.today

Dimension Therapeutics, Inc.

Total raised
$90 M
2 rounds on record
Latest round
$65 M
Apr 2015
First round on record
Oct 2013
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Dimension Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2015$65 MNo. 2$50 to $250 million

Dimension Therapeutics, Inc.: Raise no. 2, Apr 2015

Investors in this round

12 investors had bought by the notice of Apr 23, 2015: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Dimension Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$65 M of $65 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Annalisa Jenkins · Executive Officer, Director
  • Jay K. Hachigian · Executive Officer
  • Benjamin Auspitz · Director
  • Donald J. Hayden, Jr. · Director
  • Rishi Gupta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Annalisa Jenkins, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 23, 2015. Read the notice at the SEC.

equitySEC
Oct 2013$25 MNo. 1$10 to $50 million

Dimension Therapeutics, Inc.: Raise no. 1, Oct 2013

Investors in this round

2 investors had bought by the notice of Feb 11, 2015: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Dimension Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Annalisa Jenkins · Executive Officer, Director
  • Allan J. Fox · Director
  • Benjamin J. Auspitz · Director
  • Donald J. Hayden · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Annalisa Jenkins, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 11, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Dimension Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2015).

    SEC Form D · Apr 2015

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Apr 2015

That is all the official record says: Dimension Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

2 named in official filings. Open an investor to see everything it has backed.

Investors in Dimension Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Fmr LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Dimension Therapeutics, Inc.
NameRoleNamed in
Annalisa JenkinsExecutive officerApr 2015
Jay K. HachigianExecutive officerApr 2015
Thomas BeckExecutive officerNov 2013
Annalisa JenkinsDirectorApr 2015
Benjamin AuspitzDirectorApr 2015
Donald J. Hayden, Jr.DirectorApr 2015
Rishi GuptaDirectorApr 2015
Allan J. FoxDirectorFeb 2015
Benjamin J. AuspitzDirectorFeb 2015
Donald J. HaydenDirectorFeb 2015
Donald HaydenDirectorNov 2013
Thomas BeckDirectorNov 2013